Imatinib Aqvida

Imatinib, the active ingredient in Imatinib Aqvida, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor and other KIT‑positive tumors in adult patients.

GNH USA supplies Imatinib Aqvida as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets specific tyrosine‑kinase driven cancers and is used in several approved indications.

- Chronic Myeloid Leukemia (CML): achieves inhibition of leukemic cell proliferation and helps attain cytogenetic remission. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides disease control and improves overall survival. - Gastrointestinal Stromal Tumor (GIST): reduces tumor growth and delays disease progression. - Other KIT‑positive tumors: offers targeted therapy for malignancies driven by KIT mutations.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Peripheral edema - Muscle cramps or pain - Fatigue - Diarrhea - Rash or pruritus

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced ejection fraction - Pulmonary hypertension - Anaphylactic or severe allergic reactions - Tumor lysis syndrome

Before initiating therapy, clinicians should evaluate several safety parameters.

- Monitor blood counts: perform regular complete blood count tests. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: monitor ejection fraction in patients with cardiac risk. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Use caution in renal impairment: dose adjustment may be required. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Imatinib interacts with several medicines that can alter its exposure or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase imatinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce therapeutic effect. - Antacids containing aluminum or magnesium can impair absorption. - Concomitant warfarin may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors may modestly lower imatinib bioavailability. - CYP2C8 substrates (e.g., paclitaxel) may have altered plasma concentrations. - Live vaccines may have reduced efficacy; consider timing of administration.